실시간 바이오 인텔리전스 · ADC · CGT

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

8,428+프로그램
40+FDA 승인
3,743+모집 중
ADC 1032·Antibody 4683·CGT 2713차세대 추천 →·Data Tier →
8428프로그램40FDA 승인
310오늘 방문
5,436누적 방문
7303갱신 대기S–CData TierS/A/B차세대→Insight1032HER2 breast4683Antibody2713CGT→Psoriasis→NSCLC40FDA 승인
피드Data Tier차세대Insight

추천 비교

비교 도구 →
HER2 ADCEnhertu · Kadcyla · RC48CD19 CAR-TYescarta · KymriahPD-1Keytruda · Opdivo다발골수종Darzalex · BlenrepTROP2 ADCTrodelvy · Dato-DXd · SGNectin-4 · TROP2Padcev · Trodelvy건선 IL pathwayStelara · Cosentyx · SkyriziAnti-VEGF (안과)Eylea · LucentisAnti-TNFHumira · EnbrelIL-12/23Stelara · Skyrizi아토피·IL-13Dupixent · EbglyssPCSK9 · LDLRepatha · Praluent · LeqvioGLP-1 · incretinSemaglutide · Tirzepatide혈우병 유전자치료Hemgenix · Roctavian겸상적혈구 CGTCasgevy · Lyfgenia망막·DMD 유전자치료Luxturna · Elevidys

빠른 검색 · 이슈 태그

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 3,526개
다음 갱신 D-7 · 마지막 7월 21일
CGTBiologicstaleAmgenPhase 3

Avacopan (Avacopan)

Vasculitis · Vasculitis

#Vasculitis#CGT#Phase3#세포유전치료#CAR-T+3
임상시험 26상태 RECRUITING
AntibodystaleRochePhase 2

trastuzumab (Herceptin, albumin-bound paclitaxel+trastuzumab+pyrotinib)

Salivary Gland Carcinoma; Precision Therapy · Salivary Gland Carcinoma

#SalivaryGlandCarcinoma#Antibody#Phase2#항체#면역항체+3
임상시험 26상태 RECRUITING
AntibodystaleZhiyong YuPhase 2

Inetetamab (Inetetamab)

Metastatic Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+3
임상시험 26상태 ACTIVE
ADCBiologicstaleLepu Medical Technology (Beijin…Phase 3

Becotatug Vedotin (Becotatug Vedotin)

Nasopharyngeal Carcinoma (NPC) · Adenoid Cystic Carcinoma

#AdenoidCysticCarcinoma#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 26상태 RECRUITING
ADCBiologicstaleGBG Forschungs GmbHPhase 2

Phesgo (Phesgo)

HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 50%임상시험 26상태 RECRUITING
ADCBiologicstaleShanghai Hengrui Pharmaceutical…Phase 2

SHR-A2102 (SHR-A2102)

Advanced Breast Cancer; Metastatic Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 25상태 RECRUITING
CGTBiologicstaleNkarta, Inc.Phase 2

allogeneic, donor-derived NK cells (allogeneic, donor-derived NK cells)

Acute Myelogenous Leukemia · Acute Myelogenous Leukemia

#AcuteMyelogenousLeukemia#CGT#Phase2#세포유전치료#CAR-T+2
효능 ORR 4%임상시험 25상태 DISCONTINUED
ADCBiologicstaleBristol-Myers SquibbPhase 3

Amrubicin (Amrubicin)

Lung Cancer · Small Cell Lung Cancer

#SmallCellLungCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 80%임상시험 25상태 RECRUITING
ADCBiologicstaleSeagenPhase 2

brentuximab vedotin (Adcetris, Consolidation with Brentuximab Vedotin)

Hodgkin Lymphoma, Adult · Hodgkin Lymphoma, Adult

#HodgkinLymphomaAdult#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 25상태 RECRUITING
ADCBiologicstaleNational Cancer Institute (NCI)vedotin, and venetoclax dem…Phase 2

Larotrectinib (Larotrectinib)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+5
효능 ORR 94.4%임상시험 25상태 RECRUITING
AntibodystaleGalderma R&DApproved

Nemolizumab (Nemolizumab)

Psoriasis; Atopic Dermatitis · Psoriasis

#Psoriasis#Antibody#Approved#항체#면역항체+3
임상시험 25상태 RECRUITING
ADCBiologicstaleHoffmann-La RochePhase 2

POLA-R-CHP (POLA-R-CHP)

Diffuse Large B Cell Lymphoma (DLBCL) · Diffuse Large B-Cell Lymphoma (DLBCL)

#DiffuseLargeB-CellLymphomaDLBCL#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 95%임상시험 25상태 RECRUITING
CGTBiologicstaleDompé Farmaceutici S.p.APhase 1

Ex-Vivo expanded autologous IL-8 receptor (CXCR2, Ex-Vivo expanded autologous IL-8 receptor, Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells)

Brain Metastases · Glioblastoma Multiforme

#GlioblastomaMultiforme#CGT#Phase1#세포유전치료#CAR-T+3
효능 ORR 5.7%임상시험 25상태 RECRUITING
ADCBiologicstaleQuantumLeap Healthcare Collabor…Phase 2

ARV-471 (ARV-471)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 0%임상시험 24상태 RECRUITING
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

U3-1402 (U3-1402)

Metastatic Breast Cancer; Advanced Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 56%임상시험 24상태 ACTIVE
ADCBiologicstaleAstraZenecaPhase 2

AZD2936 (AZD2936)

Advanced or Metastatic NSCLC · Advanced or Metastatic NSCLC

#AdvancedorMetastaticNSCLC#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 24상태 RECRUITING
ADCBiologicstaleQuantumLeap Healthcare Collabor…Phase 2

PLX3397 (PLX3397)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 33.3%임상시험 24상태 RECRUITING
ADCBiologicstaleSpectrum Pharmaceuticals, IncPhase 1

Poziotinib (Poziotinib)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 30%임상시험 24상태 DISCONTINUED
ADCBiologicstaleDaiichi SankyoPhase 1

FL-DP (HER3-DXd, HER3-DXd (FL-DP))

Non-Small Cell Lung Cancer (NSCLC) · HER3

#HER3#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 56%임상시험 24상태 RECRUITING
ADCBiologicstaleSeagenPhase 2

brentuximab vedotin (Adcetris, Brentuximab Vedotin - induction)

Refractory Peripheral T-Cell Lymphoma; Relapsed Peripheral T-Cell Lymphoma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 2%임상시험 24상태 ACTIVE
ADCBiologicstaleGileadPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Sacituzumab Govitecan / Trastuzumab Deruxtecan)

Triple Negative Breast Neoplasms; Neoplasm Metastasis · Triple Negative Breast Neoplasms

#TripleNegativeBreastNeoplasms#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 44%임상시험 24상태 RECRUITING
ADCBiologicstaleGlaxoSmithKlinePhase 2

Dabrafenib Mesylate (Dabrafenib Mesylate)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 61%임상시험 24상태 RECRUITING
ADCSFDAFDABiologicstaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Fam-Trastuzumab Deruxtecan-Nxki)

HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer · HER2

#HER2#ADC#Phase2#FDA승인#항체약물접합체+4
효능 ORR 71.7%임상시험 23상태 RECRUITING
ADCBiologicstaleTaiho Oncology, Inc.Phase 2

Futibatinib (Futibatinib)

Advanced Solid Tumor · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 47.1%임상시험 23상태 RECRUITING
ADCBiologicstaleRochePhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, HER2,trastuzumab deruxtecan± pertuzumab)

Salivary Gland Carcinoma; Precision Therapy · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 1%임상시험 23상태 RECRUITING

28 / 142 페이지

← 이전다음 →
전체 8,428개 프로그램 보기